Weight matters: new study tracks drug levels in breast cancer patients
NCT ID NCT07195344
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study is investigating whether a patient's body weight changes how the drug Trastuzumab-Deruxtecan (T-DXd) behaves in the body. Researchers will compare drug levels and side effects between normal-weight and overweight or obese patients with advanced breast cancer. The goal is to see if weight-based dosing adjustments could improve treatment safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nîmes
RECRUITINGNîmes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Eugène Marquis
RECRUITINGRennes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Paul Strauss
RECRUITINGStrasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IUCT-O
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie - Site Paris
NOT_YET_RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest - Site Angers
NOT_YET_RECRUITINGAngers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest - Site Saint Herblain
NOT_YET_RECRUITINGSaint-Herblain, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab-Deruxtecan (T-DXd)
What this could lead to
If successful, this could help doctors personalize dosing of T-DXd based on a patient's weight, potentially improving effectiveness and reducing toxicity.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.